This study is designed to investigate whether complement C3 depletion is associated with poor short-term outcomes in postoperative patients with gastric cancer.
The complement system plays an important role in the development of digestive malignancies. The complement C3 is the point of convergence for the three complement activation pathways. However, the concrete effect of C3 in the development of gastric cancer is still obscured. This study is designed to explore whether complement C3 can be regarded as a predictive factor of postoperative outcomes for postoperative patients with gastric cancer. This study is designed as a prospective cohort study and included consecutively treated patients. The perioperative plasma value of complement components, such as C3, C4, and CH50, are detected to explore the incidence rate of complement depletion. All enrolled patients are divided into two groups mainly according to the levels of preoperative C3 levels (C3 depletion and Non-C3 depletion groups). The primary endpoints are the 1-year overall survival and disease-free survival, while the secondary endpoints are postoperative complications, length of hospital stay, and hospital charges. This study would be helpful to confirm the role of complement depletion in anticipated outcomes of postoperative patients with gastric cancer.
Study Type
OBSERVATIONAL
Enrollment
85
A classic total or subtotal gastrectomy plus D2 lymph nodes dissection would be performed for all enrolled patients. Patients in both groups would undergo the identical therapeutic approach for gastric cancer, mainly decided by a multidisciplinary treatment group in our center.
A postoperative systemic chemotherapy would be performed for some subjects who have advanced gastric cancer. The concrete chemo regimen for adjuvant chemotherapy is also determined by a MDT group. Generally, SOX chemo regimen is the first-line treatment in our center, as following described: * S-1: 40\~60mg bid，po, Day1\~14 （S-1：BSA \<1.25m2, 40mg bid, 1.25m2≤BSA≤1.5m2,50mg bid, BSA\>1.5m2, 60mg bid） * Oxaliplatin: 130mg/m2，iv drip for 2h，Day1
The First Affiliated Hospital of Sun Yat-sen University
Guangzhou, Guangdong, China
Overall Survival
1-year overall survival (OS) would be regarded as primary endpoint of this study.
Time frame: one year after surgery
Disease-Free Survival
1-year disease-free survival (DFS) would be also regarded as primary endpoint of this study.
Time frame: One year after surgery
Early complications
Early postoperative events should include intra-abdominal infection, postoperative hemorrhage, anastomotic leak, surgical site infection, ileus, and so on. Number of such events would be recorded to calculate incidence.
Time frame: within 30 days after a radical operation
Length of hospital stay
Time frame would cover the period from admission to discharge from hospital. An average of 4 weeks is expected.
Time frame: an expected average of 4 weeks after admission
Expenditure of hospitalization
The total costs during the hospitalization would be summarized.
Time frame: an expected average of 4 weeks after admission
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.